for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead-Galapagos's drug meets main goals of ulcerative colitis study

May 20 (Reuters) - Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.

Filgotinib is being tested for inflammatory conditions including rheumatoid arthritis and Crohn's disease. (reut.rs/2Tmy9fO) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up